DermTech, Inc. (NASDAQ:DMTK – Get Rating) COO Claudia Ibarra sold 2,449 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $5.65, for a total value of $13,836.85. Following the completion of the transaction, the chief operating officer now directly owns 161,105 shares in the company, valued at $910,243.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Claudia Ibarra also recently made the following trade(s):
Get
DermTech alerts:
- On Tuesday, September 6th, Claudia Ibarra sold 133 shares of DermTech stock. The shares were sold at an average price of $5.43, for a total value of $722.19.
- On Monday, June 13th, Claudia Ibarra sold 345 shares of DermTech stock. The shares were sold at an average price of $4.81, for a total value of $1,659.45.
DermTech Trading Down 1.5 %
Shares of DMTK stock opened at $5.97 on Friday. The company has a market capitalization of $179.34 million, a P/E ratio of -1.68 and a beta of 1.49. The business's 50 day moving average is $6.57 and its two-hundred day moving average is $8.59. DermTech, Inc. has a 12-month low of $4.18 and a 12-month high of $36.80.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on DMTK shares. BTIG Research cut their price objective on DermTech from $19.00 to $15.00 and set a "buy" rating on the stock in a report on Monday, August 15th. Lake Street Capital lowered their target price on DermTech from $34.00 to $14.00 in a research note on Tuesday, August 9th. Oppenheimer lowered their target price on DermTech from $48.00 to $23.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 17th. Finally, Craig Hallum lowered their target price on DermTech from $37.00 to $18.00 in a research note on Tuesday, August 9th.
Hedge Funds Weigh In On DermTech
Hedge funds have recently bought and sold shares of the business. Wolverine Asset Management LLC purchased a new position in DermTech during the fourth quarter worth approximately $43,000. Amalgamated Bank purchased a new position in shares of DermTech in the first quarter valued at approximately $58,000. Financial Management Professionals Inc. purchased a new position in shares of DermTech in the second quarter valued at approximately $26,000. Ensign Peak Advisors Inc purchased a new position in shares of DermTech in the fourth quarter valued at approximately $82,000. Finally, Integrated Advisors Network LLC purchased a new position in shares of DermTech in the first quarter valued at approximately $147,000. Hedge funds and other institutional investors own 58.74% of the company's stock.
About DermTech
(Get Rating)
DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
Featured Articles
- Get a free copy of the StockNews.com research report on DermTech (DMTK)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.
